Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. (NCT03229200)
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
🩺 Plain-English Summary (8th-Grade Level)
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Who can join: Review the eligibility criteria below.
Location: Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center — Burbank, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (98 Sites)
Showing the first 25 of 98 sites.
- Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center — Burbank, California
- City Of Hope National Medical Center — Duarte, California
- UCSD Moores Cancer Center — La Jolla, California
- University of California Los Angeles (UCLA) — Los Angeles, California
- Stanford University — Stanford, California
- Emory University — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- Norton Medical Plaza II, 3991 Dutchmans Lane — Louisville, Kentucky
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- TRIO - Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- John Theurer Cancer Center, Hackensack UMC — Hackensack, New Jersey
- San Juan Oncology Associates — Farmington, New Mexico
- Northwell Health — New Hyde Park, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medical College-New York Presbyterian Hospital — New York, New York
- University of Rochester — Rochester, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Southeastern Medical Oncology Center — Goldsboro, North Carolina
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- The Ohio State University — Columbus, Ohio
- Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center — Columbus, Ohio
- University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, B-Cell
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — Scottsdale, Arizona
- FT819 in Subjects With B-cell Malignancies — Birmingham, Alabama
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma — Vancouver, British Columbia
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma — Birmingham, Alabama
- Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — New York, New York
Explore by condition: All Lymphoma, B-Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.